Bileductcancer
PCI Biotech $PCIB.OL top 10 hot nordic stocks @veckansaffarer
www.va.se
finansavisen.no
PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities.
The company is applying PCI to three distinct anticancer paradigms:
• fimaCHEM – enhancement of chemotherapeutics for localised treatment of cancer
• fimaVACC – enhanced T-cell induction for therapeutic vaccination
• fimaNAc – nucleic acid therapeutics delivery
The company’s lead fimaCHEM programme consists of a pivotal clinical study with registration intent of Amphinex® in bile duct cancer, an orphan indication with a high-unmet need and without approved products. Clinical proof-of-concept has been achieved in the fimaVACC programme, which applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines. The fimaNAc programme utilises the triggered endosomal release to provide effective intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising class of therapeutics.
PCI Biotech $PCIB.OL testing breakout from yearlong downtrendPCI Biotech Holding OSL:PCIB stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million.
Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines:
www.tu.no (norwegian language)
nordiclifescience.org (page 91-94)
At the moment, the stock is testing a breakout from the old trading range, and longs will be keen to see further conference or scientific journal coverage of the ongoing clinical programs for the companys FimaCHEM and FimaVACC products, as well as partnering deals for its FimaNAC product.
